SCHEMBL2227178

SCHEMBL2227178

NS(=O)(=O)c1ccc(OC(F)(F)F)c(CNc2cc(Nc3ccc(Cl)cn3)ncn2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNNI3K Q59H18 6/20 0.61
BRAF P15056 6/20 0.52
EGFR P00533 1/20 0.41
ABL1 P00519 2/20 0.41
BCR P11274 2/20 0.41
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
STAT3 P40763 1/20 0.39
MAPK10 P53779 1/20 0.38
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK5 Q00535 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225876 0.90 BRAF (0.63) TNNI3KBRAFEGFRABL1BCR
SCHEMBL2225574 0.89 TNNI3K (0.59) TNNI3KEGFRABL1BCRLMNA
SCHEMBL2225756 0.88 BRAF (0.62) TNNI3KBRAFEGFRLMNASMN1; SMN2
SCHEMBL2226387 0.87 BRAF (0.51) TNNI3KBRAFEGFRLMNASMN1; SMN2
SCHEMBL2225100 0.83 ABL1 (0.48) TNNI3KEGFRABL1BCRLMNA
SCHEMBL2226261 0.81 TNNI3K (0.58) TNNI3KBRAFEGFRMAPK10CDK1
SCHEMBL2225873 0.80 TNNI3K (0.46) TNNI3KBRAFEGFRMAPK10SLC6A4
SCHEMBL2225786 0.80 BRAF (0.50) TNNI3KBRAFEGFRABL1BCR
SCHEMBL2228424 0.79 TNNI3K (0.61) TNNI3KBRAFEGFRABL1BCR
SCHEMBL2226032 0.79 BRAF (0.60) TNNI3KBRAFEGFRALDH1A1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP claimed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO claimed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed